Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 89.71 billion. The enterprise value is 72.23 billion.

Market Cap	89.71B
Enterprise Value	72.23B

Important Dates

The last earnings date was Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Genmab has 61.51 million shares outstanding. The number of shares has decreased by -3.37% in one year.

Current Share Class	61.51M
Shares Outstanding	61.51M
Shares Change (YoY)	-3.37%
Shares Change (QoQ)	-85.95%
Owned by Insiders (%)	1.12%
Owned by Institutions (%)	51.50%
Float	60.81M

Valuation Ratios

The trailing PE ratio is 10.62 and the forward PE ratio is 13.24. Genmab's PEG ratio is 2.51.

PE Ratio	10.62
Forward PE	13.24
PS Ratio	3.87
PB Ratio	2.66
P/TBV Ratio	4.42
P/FCF Ratio	12.95
P/OCF Ratio	12.45
PEG Ratio	2.51

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.46, with an EV/FCF ratio of 10.42.

EV / Earnings	8.30
EV / Sales	3.12
EV / EBITDA	8.46
EV / EBIT	8.92
EV / FCF	10.42

Financial Position

The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.03.

Current Ratio	6.22
Quick Ratio	6.20
Debt / Equity	0.03
Debt / EBITDA	0.11
Debt / FCF	0.14
Interest Coverage	49.22

Financial Efficiency

Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 15.86%.

Return on Equity (ROE)	28.12%
Return on Assets (ROA)	13.26%
Return on Invested Capital (ROIC)	15.86%
Return on Capital Employed (ROCE)	21.84%
Revenue Per Employee	8.78M
Profits Per Employee	3.30M
Employee Count	2,682
Asset Turnover	0.61
Inventory Turnover	21.91

Taxes

In the past 12 months, Genmab has paid 1.16 billion in taxes.

Income Tax	1.16B
Effective Tax Rate	11.77%

Stock Price Statistics

The stock price has decreased by -19.26% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-19.26%
50-Day Moving Average	1,400.91
200-Day Moving Average	1,439.28
Relative Strength Index (RSI)	55.89
Average Volume (20 Days)	115,300

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 23.16 billion and earned 8.71 billion in profits. Earnings per share was 137.33.

Revenue	23.16B
Gross Profit	21.90B
Operating Income	8.10B
Pretax Income	9.87B
Net Income	8.71B
EBITDA	8.43B
EBIT	8.10B
Earnings Per Share (EPS)	137.33

Full Income Statement

Balance Sheet

The company has 18.41 billion in cash and 940.09 million in debt, giving a net cash position of 17.47 billion or 284.10 per share.

Cash & Cash Equivalents	18.41B
Total Debt	940.09M
Net Cash	17.47B
Net Cash Per Share	284.10
Equity (Book Value)	33.68B
Book Value Per Share	547.59
Working Capital	20.84B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.21 billion and capital expenditures -275.93 million, giving a free cash flow of 6.93 billion.

Operating Cash Flow	7.21B
Capital Expenditures	-275.93M
Free Cash Flow	6.93B
FCF Per Share	112.67

Full Cash Flow Statement

Margins

Gross margin is 94.54%, with operating and profit margins of 34.95% and 37.59%.

Gross Margin	94.54%
Operating Margin	34.95%
Pretax Margin	42.60%
Profit Margin	37.59%
EBITDA Margin	36.40%
EBIT Margin	34.95%
FCF Margin	29.91%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.37%
Shareholder Yield	n/a
Earnings Yield	9.71%
FCF Yield	7.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.99 and a Piotroski F-Score of 5.

Altman Z-Score	9.99
Piotroski F-Score	5